Skip to main content

Enliven Therapeutics, Inc.

corporate_fare Company Profile

Enliven Therapeutics, Inc.

ELVN·NASDAQ·Life Sciences·CIK 0001672619

We are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics. Our goal is to improve survival and overall well-being by addressing unmet medical needs through a precision medicine approach. We combine insights into clinically validated biological targets with differentiated chemistry to design therapies. Our development process involves validated targets, which are those with demonstrated roles in disease pathology, along with specific target product profiles, disciplined clinical trial design, and regulatory strategy. We are currently developing ELVN-001 and pursuing additional research-stage opportunities. ELVN-001 is a potent, highly selective, small molecule kinase inhibitor designed to target the breakpoint cluster region - Abelson ("BCR-ABL") gene fusion, which drives chronic myeloid leukemia ("CML"). It is an adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor (TKI) that blocks phosphorylation and oncogenic signaling by competing with ATP for binding at the kinase active site. While BCR-ABL TKIs have transformed CML prognosis, patients still face challenges such as primary or secondary resistance to existing TKIs, off-target activity of ATP-competitive TKIs (e.g., nilotinib, dasatinib) leading to adverse events, drug-drug interactions, and adherence difficulties due to specific food requirements for most BCR-ABL TKIs.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ELVN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Enliven Therapeutics Appoints Biopharma Veteran Scott Garland to Board, Bolstering Commercialization Expertise for Phase 3

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$103.69M
Diluted EPS
-$1.83
Op. Cash Flow
-$70.3M
Free Cash Flow
-$70.46M
Operating Income
-$119.66M
Cash & Equivalents
$98.9M
Debt / Equity
0.00×
Shares Outstanding
59.44M sh
Source: 10-K · filed 2026-03-03 · accession 0001193125-26-088232
$46.53
52-week range · as of 2026-11-05 $14.79 – $62.32
Market cap
$3.42B
Volume
933.6K (0.7× avg)
3-mo avg 1.4M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ELVN - Filings & News (Page 2)

ELVN
Jan 07, 2026, 9:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.14
Real-time Price: $46.53 info
Change: +$31.39 (+207%) info
Market Cap: $3.424B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets